• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 8-K filed by Walgreens Boots Alliance Inc.

    7/11/25 4:30:33 PM ET
    $WBA
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples
    Get the next $WBA alert in real time by email
    8-K
    false 0001618921 0001618921 2025-07-11 2025-07-11 0001618921 us-gaap:CommonStockMember 2025-07-11 2025-07-11 0001618921 wba:M3.600WalgreensBootsAllianceInc.NotesDue20252Member 2025-07-11 2025-07-11 0001618921 wba:M2.125WalgreensBootsAllianceInc.NotesDue20261Member 2025-07-11 2025-07-11
     
     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    FORM 8-K

     

     

    CURRENT REPORT

    Pursuant to Section 13 or 15(d)

    of the Securities Exchange Act of 1934

    Date of Report (Date of earliest event reported): July 11, 2025

     

     

    WALGREENS BOOTS ALLIANCE, INC.

    (Exact name of registrant as specified in its charter)

     

     

     

    Delaware   001-36759   47-1758322
    (State or other jurisdiction
    of incorporation)
      (Commission
    File Number)
      (IRS Employer
    Identification Number)

     

    108 Wilmot Road, Deerfield, Illinois   60015
    (Address of principal executive offices)   (Zip Code)

    Registrant’s telephone number, including area code: (847) 315-3700

    Not Applicable

    (Former name or former address, if changed since last report)

     

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Registrant under any of the following provisions:

     

    ☐

    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

     

    ☐

    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

     

    ☐

    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

     

    ☐

    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Securities registered pursuant to Section 12(b) of the Securities Exchange Act of 1934:

     

    Title of each class

     

    Trading
    Symbol(s)

     

    Name of each exchange
    on which registered

    Common Stock, $0.01 par value   WBA   The Nasdaq Stock Market LLC
    3.600% Walgreens Boots Alliance, Inc. notes due 2025   WBA25   The Nasdaq Stock Market LLC
    2.125% Walgreens Boots Alliance, Inc. notes due 2026   WBA26   The Nasdaq Stock Market LLC

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

    Emerging growth company ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     
     


    Item 5.07.

    Submission of Matters to a Vote of Security Holders.

    As previously disclosed, on March 6, 2025, Walgreens Boots Alliance, Inc., a Delaware corporation (the “Company”) entered into an Agreement and Plan of Merger (the “Merger Agreement”) with Blazing Star Parent, LLC, a Delaware limited liability company (“Parent”), Blazing Star Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (“Merger Sub”), and the other affiliates of Parent named therein (collectively, together with Parent and Merger Sub, the “Parent Entities”), pursuant to which, subject to the terms and conditions set forth therein, Merger Sub will be merged with and into the Company, with the Company surviving the Merger as a wholly owned subsidiary of Parent (the “Merger”). As a result of the Merger, the Company will cease to be a publicly traded company.

    On July 11, 2025, the Company held a special meeting of stockholders (the “Special Meeting”) to consider certain proposals related to the Merger Agreement.

    As of June 6, 2025, the record date (the “Record Date”) for the Special Meeting, there were 865,560,675 shares of the common stock of the Company, par value $0.01 per share (“Company Common Stock”), outstanding, each of which was entitled to one vote on each matter considered at the Special Meeting. As of the Record Date, there were 717,727,706 shares of Company Common Stock held by holders other than Stefano Pessina, John Lederer, Parent and any of their respective affiliates (the “Unaffiliated Stockholders”). A total of 648,219,746 shares of Company Common Stock, representing approximately 74.89% of the voting power of the outstanding shares of the Company’s Common Stock entitled to vote, were present or represented by proxy at the Special Meeting, constituting a quorum to conduct business.

    The Special Meeting was held to consider the following proposals:

     

      1.

    Merger Agreement Proposal. A proposal to adopt the Merger Agreement, pursuant to which, subject to the terms and conditions set forth therein and among other things, Merger Sub will be merged with and into the Company, with the Company surviving the Merger as a wholly owned subsidiary of Parent (the “Merger Agreement Proposal”).

     

      2.

    Adjournment Proposal. A proposal to adjourn the Special Meeting, from time to time, to a later date or dates if necessary or appropriate, including adjournments to solicit additional proxies if there are insufficient votes at the time of the Special Meeting to approve the Merger Agreement Proposal (the “Adjournment Proposal”).

     

      3.

    Merger-Related Compensation Proposal. A proposal to approve, by a nonbinding, advisory vote, certain compensation that may become payable to the Company’s named executive officers in connection with the completion of the Merger (the “Merger-Related Compensation Proposal”).

    Each proposal is described in detail in the Company’s definitive proxy statement filed with the Securities and Exchange Commission on June 6, 2025 and first mailed to the Company’s stockholders on June 6, 2025. The Merger Agreement and the Merger-Related Compensation Proposal were each approved by the requisite vote of the Company’s stockholders. The final voting results for each proposal are described below.

    The Merger Agreement Proposal

    Approval of the proposal to adopt the Merger Agreement required both the affirmative vote of (i) the holders of a majority of the outstanding shares of Company Common Stock entitled to vote on such matter at the Special Meeting (the “Majority of the Outstanding Shares”) and (ii) the holders of a majority of the outstanding shares of Company Common Stock held by the Unaffiliated Stockholders cast on such matter at the Special Meeting (the “Majority of the Unaffiliated Shares Cast”). A total of 500,386,777 shares of Company Common Stock held by the Unaffiliated Stockholders were cast on this matter at the Special Meeting.

     

         For      Against      Abstain  

    Majority of the Outstanding Shares

         626,190,387        20,140,186        1,889,173  

    Majority of the Unaffiliated Shares Cast

         478,357,418        20,140,186        1,889,173  

    The Merger Agreement was approved by the requisite votes of the Company’s stockholders.

     

    2


    The Merger-Related Compensation Proposal

    Approval on a nonbinding advisory basis of the Merger-Related Compensation Proposal required the affirmative vote of a majority of the shares of Company Common Stock present in person or by proxy at the Special Meeting and entitled to vote on the Merger-Related Compensation Proposal.

     

    For    Against    Abstain
    608,730,038    34,916,603    4,573,105

    The Merger-Related Compensation Proposal was approved on a nonbinding advisory basis.

    In light of the approval of the Merger Agreement Proposal, the Adjournment Proposal was rendered moot and was not presented at the Special Meeting. There were no recorded broker non-votes.

     

    Item 8.01.

    Other Events.

    On July 11, 2025, the Company issued a press release announcing the preliminary results of the Special Meeting. A copy of the press release is attached as Exhibit 99.1 hereto and incorporated herein by reference.

     

    Item 9.01.

    Financial Statements and Exhibits.

     

    (d)

    Exhibits

     

    Exhibit

      

    Description

    99.1    Press Release of Walgreens Boots Alliance, Inc. dated July 11, 2025
    104    Cover Page Interactive Data File (embedded within the Inline XBRL document)

     

    3


    SIGNATURE

    Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

      WALGREENS BOOTS ALLIANCE, INC.
    Date: July 11, 2025     By:  

    /s/ Lanesha Minnix

        Name: Lanesha Minnix
        Title:Executive Vice President, Global Chief Legal Officer and Corporate Secretary

     

    4

    Get the next $WBA alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $WBA

    DatePrice TargetRatingAnalyst
    2/28/2025$11.00 → $9.00Hold → Sell
    Deutsche Bank
    2/26/2024$23.00Market Perform
    Leerink Partners
    2/20/2024Hold → Reduce
    HSBC Securities
    1/3/2024$21.00Underweight
    Barclays
    12/22/2023$27.00Hold
    HSBC Securities
    10/23/2023$27.00 → $30.00Neutral → Overweight
    JP Morgan
    7/3/2023$37.00 → $27.00Underweight
    Morgan Stanley
    6/28/2023$46.00 → $34.00Buy → Hold
    Deutsche Bank
    More analyst ratings

    $WBA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Walgreens Boots Alliance downgraded by Deutsche Bank with a new price target

      Deutsche Bank downgraded Walgreens Boots Alliance from Hold to Sell and set a new price target of $9.00 from $11.00 previously

      2/28/25 7:36:45 AM ET
      $WBA
      Retail-Drug Stores and Proprietary Stores
      Consumer Staples
    • Leerink Partners initiated coverage on Walgreens Boots Alliance with a new price target

      Leerink Partners initiated coverage of Walgreens Boots Alliance with a rating of Market Perform and set a new price target of $23.00

      2/26/24 8:28:07 AM ET
      $WBA
      Retail-Drug Stores and Proprietary Stores
      Consumer Staples
    • Walgreens Boots Alliance downgraded by HSBC Securities

      HSBC Securities downgraded Walgreens Boots Alliance from Hold to Reduce

      2/20/24 10:23:30 AM ET
      $WBA
      Retail-Drug Stores and Proprietary Stores
      Consumer Staples

    $WBA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Executive Chairman of Board Pessina Stefano sold $9,163,161 worth of shares (832,258 units at $11.01) and bought $9,163,161 worth of shares (832,258 units at $11.01), decreasing direct ownership by 56% to 657,308 units (SEC Form 4)

      4 - Walgreens Boots Alliance, Inc. (0001618921) (Issuer)

      4/29/25 8:49:21 PM ET
      $WBA
      Retail-Drug Stores and Proprietary Stores
      Consumer Staples
    • Bhandari Inderpal S bought $54,150 worth of shares (3,000 units at $18.05) (SEC Form 4)

      4 - Walgreens Boots Alliance, Inc. (0001618921) (Issuer)

      4/15/24 5:45:26 PM ET
      $WBA
      Retail-Drug Stores and Proprietary Stores
      Consumer Staples
    • Mahajan Manmohan bought $116,280 worth of shares (6,000 units at $19.38) (SEC Form 4)

      4 - Walgreens Boots Alliance, Inc. (0001618921) (Issuer)

      4/2/24 6:40:23 PM ET
      $WBA
      Retail-Drug Stores and Proprietary Stores
      Consumer Staples

    $WBA
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • September 12, 2023 - FDA Issues Warning Letters to Firms Marketing Unapproved Eye Products

      For Immediate Release: September 12, 2023 The U.S. Food and Drug Administration has issued warning letters to eight companies for manufacturing or marketing unapproved ophthalmic drug products in violation of federal law. These warning letters are part of the agency’s ongoing effort to protect Americans from potentially harmful ophthalmic products. Eye products addressed in the eight warning letters are illegal

      9/12/23 10:44:21 AM ET
      $WBA
      Retail-Drug Stores and Proprietary Stores
      Consumer Staples

    $WBA
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Walgreens Boots Alliance Shareholders Overwhelmingly Approve Transaction with Sycamore Partners

      Transaction expected to close in the third or fourth quarter of calendar year 2025 Walgreens Boots Alliance, Inc. (NASDAQ:WBA) (the "Company" or "WBA") today announced that at the Company's Special Meeting of Shareholders (the "Special Meeting"), WBA shareholders approved the previously announced acquisition of the Company by entities affiliated with Sycamore Partners Management, L.P. ("Sycamore"). According to the preliminary results, approximately 96% of votes cast at the Special Meeting by all shareholders were voted in favor of the merger agreement proposal. In addition, approximately 95% of the votes cast at the Special Meeting by unaffiliated shareholders were voted in favor of th

      7/11/25 9:59:00 AM ET
      $WBA
      Retail-Drug Stores and Proprietary Stores
      Consumer Staples
    • Walgreens Boots Alliance Reports Fiscal 2025 Third Quarter Results

      Third quarter financial results Third quarter loss per share1 was $0.20 compared to earnings per share of $0.40 in the year-ago quarter. The decline in earnings per share was primarily driven by prior year after-tax gains related to fair value adjustments on variable prepaid forward derivatives and a partial sale of the Company's equity method investment in Cencora, and higher tax expense in the current quarter. Adjusted earnings per share (EPS)2 was $0.38 compared to adjusted EPS2 of $0.63 in the year-ago quarter. The decline in adjusted EPS2 was primarily driven by a higher adjusted effective tax rate2, higher incentive accruals, lower U.S. retail sales and lower equity earnings in

      6/26/25 7:00:00 AM ET
      $WBA
      Retail-Drug Stores and Proprietary Stores
      Consumer Staples
    • Walgreens and KFF's Greater Than Campaign to Offer Free HIV/STD Testing in Stores on June 27

      More than 415 local health departments and community organizations mobilize across the country for largest-ever National HIV Testing Day event Walgreens and Greater Than HIV/STDs, a public information campaign from KFF, are joining with health departments and community organizations to provide free rapid HIV, syphilis and hepatitis C testing at more than 575 Walgreens stores on June 27 for the nation's largest National HIV Testing Day (NHTD) event. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250612760766/en/ With more than 415 local testing partners in nearly all states, Washington, D.C. and Puerto Rico, this year's activat

      6/12/25 9:00:00 AM ET
      $WBA
      Retail-Drug Stores and Proprietary Stores
      Consumer Staples

    $WBA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Huffines Robert Luther

      4 - Walgreens Boots Alliance, Inc. (0001618921) (Issuer)

      7/11/25 5:21:10 PM ET
      $WBA
      Retail-Drug Stores and Proprietary Stores
      Consumer Staples
    • SEC Form 4 filed by Director Jarrett Valerie B

      4 - Walgreens Boots Alliance, Inc. (0001618921) (Issuer)

      7/11/25 5:19:48 PM ET
      $WBA
      Retail-Drug Stores and Proprietary Stores
      Consumer Staples
    • SEC Form 4 filed by Director Lederer John Anthony

      4 - Walgreens Boots Alliance, Inc. (0001618921) (Issuer)

      7/11/25 5:15:15 PM ET
      $WBA
      Retail-Drug Stores and Proprietary Stores
      Consumer Staples

    $WBA
    Financials

    Live finance-specific insights

    See more
    • Walgreens Boots Alliance Shareholders Overwhelmingly Approve Transaction with Sycamore Partners

      Transaction expected to close in the third or fourth quarter of calendar year 2025 Walgreens Boots Alliance, Inc. (NASDAQ:WBA) (the "Company" or "WBA") today announced that at the Company's Special Meeting of Shareholders (the "Special Meeting"), WBA shareholders approved the previously announced acquisition of the Company by entities affiliated with Sycamore Partners Management, L.P. ("Sycamore"). According to the preliminary results, approximately 96% of votes cast at the Special Meeting by all shareholders were voted in favor of the merger agreement proposal. In addition, approximately 95% of the votes cast at the Special Meeting by unaffiliated shareholders were voted in favor of th

      7/11/25 9:59:00 AM ET
      $WBA
      Retail-Drug Stores and Proprietary Stores
      Consumer Staples
    • Walgreens Boots Alliance Reports Fiscal 2025 Third Quarter Results

      Third quarter financial results Third quarter loss per share1 was $0.20 compared to earnings per share of $0.40 in the year-ago quarter. The decline in earnings per share was primarily driven by prior year after-tax gains related to fair value adjustments on variable prepaid forward derivatives and a partial sale of the Company's equity method investment in Cencora, and higher tax expense in the current quarter. Adjusted earnings per share (EPS)2 was $0.38 compared to adjusted EPS2 of $0.63 in the year-ago quarter. The decline in adjusted EPS2 was primarily driven by a higher adjusted effective tax rate2, higher incentive accruals, lower U.S. retail sales and lower equity earnings in

      6/26/25 7:00:00 AM ET
      $WBA
      Retail-Drug Stores and Proprietary Stores
      Consumer Staples
    • Walgreens Boots Alliance Reports Fiscal 2025 Second Quarter Results

      Second quarter financial results Second quarter loss per share1 was $3.30 compared to loss per share of $6.85 in the year-ago quarter. Second quarter results include $4.2 billion of non-cash impairment charges attributable to WBA, net of tax and non-controlling interest, related to goodwill, intangible and other long-lived assets primarily at U.S. Retail Pharmacy and VillageMD, and $1.0 billion of after-tax gains related to asset monetization activities. Adjusted earnings per share (EPS)2 was $0.63 compared to adjusted EPS2 of $1.20 in the year-ago quarter. The decline in adjusted EPS2 was primarily driven by prior year adjusted effective tax benefit2, lower U.S. retail sales and prior

      4/8/25 7:00:00 AM ET
      $WBA
      Retail-Drug Stores and Proprietary Stores
      Consumer Staples

    $WBA
    SEC Filings

    See more
    • Amendment: SEC Form SC 13E3/A filed by Walgreens Boots Alliance Inc.

      SC 13E3/A - Walgreens Boots Alliance, Inc. (0001618921) (Subject)

      7/11/25 4:34:10 PM ET
      $WBA
      Retail-Drug Stores and Proprietary Stores
      Consumer Staples
    • SEC Form 8-K filed by Walgreens Boots Alliance Inc.

      8-K - Walgreens Boots Alliance, Inc. (0001618921) (Filer)

      7/11/25 4:30:33 PM ET
      $WBA
      Retail-Drug Stores and Proprietary Stores
      Consumer Staples
    • SEC Form DEFA14A filed by Walgreens Boots Alliance Inc.

      DEFA14A - Walgreens Boots Alliance, Inc. (0001618921) (Filer)

      7/3/25 7:02:47 AM ET
      $WBA
      Retail-Drug Stores and Proprietary Stores
      Consumer Staples

    $WBA
    Leadership Updates

    Live Leadership Updates

    See more
    • Walgreens Appoints Jason Stenta as SVP and Chief Commercial Officer

      Stenta will lead B2B commercial growth strategy as the company strengthens its role as the first choice for community pharmacy and health services in the U.S. Walgreens, an integrated healthcare, pharmacy and retail leader serving millions of customers and patients every day, today announced the appointment of Jason Stenta as SVP and chief commercial officer. In this new role, Stenta will lead the company's commercial growth strategy, driving development and commercialization of B2B healthcare services built on the company's core assets, and enhancing partnerships with payers, health system providers and life sciences companies. This press release features multimedia. View the full release

      10/7/24 8:00:00 AM ET
      $WBA
      Retail-Drug Stores and Proprietary Stores
      Consumer Staples
    • Walgreens Appoints Two New Leaders to its Retail and Customer Experience Team

      Names Tracey Koller as Chief Merchandising Officer and Sharmila Sudhakar as Group Vice President and Head of Digital Commerce Walgreens, the leading independent retail pharmacy and healthcare provider, today announced two key leadership appointments: Tracey Koller, senior vice president and chief merchandising officer, and Sharmila Sudhakar, group vice president and head of Walgreens digital commerce. The company believes these new appointments will significantly contribute to its efforts with regard to the turnaround of the business as the company focuses on enhancing the front of store and omnichannel experience for its customers while driving in-store efficiencies. This press release

      8/16/24 9:00:00 AM ET
      $WBA
      Retail-Drug Stores and Proprietary Stores
      Consumer Staples
    • Super Micro Computer Inc. to Join the Nasdaq-100 Index® Beginning July 22, 2024

      NEW YORK, July 12, 2024 (GLOBE NEWSWIRE) -- Nasdaq (NASDAQ:NDAQ) today announced that Super Micro Computer Inc. (NASDAQ:SMCI), will become a component of the Nasdaq-100 Index® (NASDAQ:NDX) and the Nasdaq-100 Equal Weighted™ Index (NASDAQ:NDXE) prior to market open on Monday, July 22, 2024. Super Micro Computer Inc. will replace Walgreens Boots Alliance Inc. (NASDAQ:WBA) in the Nasdaq-100 Index® and the Nasdaq-100 Equal Weighted Index. Walgreens Boots Alliance Inc. will also be removed from the Nasdaq-100 Ex-Tech Sector™ Index (NASDAQ:NDXX), the Nasdaq-100 ESG™ Index (NASDAQ:NDXESG), and the Nasdaq-100 Sustainable ESG Select™ Index (NASDAQ:NDXSES) on the same date. Super Micro Computer Inc

      7/12/24 8:00:00 PM ET
      $NDAQ
      $SMCI
      $WBA
      Investment Bankers/Brokers/Service
      Finance
      Computer Manufacturing
      Technology

    $WBA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Walgreens Boots Alliance Inc.

      SC 13G/A - Walgreens Boots Alliance, Inc. (0001618921) (Subject)

      10/18/24 12:45:41 PM ET
      $WBA
      Retail-Drug Stores and Proprietary Stores
      Consumer Staples
    • Amendment: SEC Form SC 13D/A filed by Walgreens Boots Alliance Inc.

      SC 13D/A - Walgreens Boots Alliance, Inc. (0001618921) (Filed by)

      8/20/24 4:05:58 PM ET
      $WBA
      Retail-Drug Stores and Proprietary Stores
      Consumer Staples
    • SEC Form SC 13G/A filed by Walgreens Boots Alliance Inc. (Amendment)

      SC 13G/A - Walgreens Boots Alliance, Inc. (0001618921) (Subject)

      2/13/24 5:17:30 PM ET
      $WBA
      Retail-Drug Stores and Proprietary Stores
      Consumer Staples